Sanofi to buy Inhibrx for $1.7 billion
PARIS, FRANCE: Sanofi, a global pharmaceutical company, has agreed to acquire Inhibrx, a clinical-stage biotech firm, for $30.0 per share in cash, or about $1.7...
Aptamer Group partners with biotech firm to target genetic medicines with Optimers
LONDON: Aptamer Group plc, a company that develops novel Optimer binders for the life sciences industry, has signed a deal with a biotech firm that...